PD-L1 in melanoma
1 EU-approved indication in melanoma needs a PD-L1 result: relatlimab + nivolumab (1st line, advanced).
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| PD-L11 | ||||
Opdualag | TPS < 1% | Monotherapy | 1L advanced | Aged 12 years and older |
8 approvals for Melanoma need no biomarker and apply whatever the result. All approvals for Melanoma
See also
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Relatlimab + nivolumab (Opdualag)
Opdualag is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%.